Quantification of boron in cells for evaluation of drug agents used in boron neutron capture therapy

2021 ◽  
Author(s):  
B. Verlinden ◽  
K. Van Hoecke ◽  
A. Aerts ◽  
N. Daems ◽  
A. Dobney ◽  
...  
Keyword(s):  
Nitric Acid ◽  
Neutron Capture ◽  
Preparation Method ◽  
Neutron Capture Therapy ◽  
Acid Digestion ◽  
Sample Preparation Method ◽  
Drug Candidates ◽  
Boron Neutron Capture ◽  
Icp Ms ◽  
Nitric Acid Digestion

The combination of UV digestion and nitric acid digestion is an effective sample preparation method for the quantification of boron in cell cultures by ICP-MS in the context of screening BNCT drug candidates for cancer treatment.

scholarly journals Therapeutic Pretargeting with Gold Nanoparticles as Drug Candidates for Boron Neutron Capture Therapy

2020 ◽  
Vol 37 (12) ◽  
pp. 2000200 ◽  
Author(s):  
Irene V. J. Feiner ◽  
Krishna R. Pulagam ◽  
Vanessa Gómez‐Vallejo ◽  
Kepa Zamacola ◽  
Zuriñe Baz ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Drug Candidates ◽  
Boron Neutron Capture

scholarly journals Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy

2021 ◽  
Author(s):  
Irene V. J. Feiner ◽  
Krishna R. Pulagam ◽  
Kepa B. Uribe ◽  
Rossana Passannante ◽  
Cristina Simó ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Neutron Capture ◽  
Carbon Dots ◽  
Emission Tomography ◽  
Neutron Capture Therapy ◽  
Drug Candidates ◽  
Boron Neutron Capture ◽  
Positron Emission ◽  
Small Nanoparticles ◽  
Boron Carbon

Tetrazine-functionalised boron-rich carbon dots show fast clearance and enhanced tumour accumulation under pre-targeting conditions, as demonstrated using positron emission tomography.

scholarly journals A Study of The Assessment for Boron Neutron Capture Therapy Agent

2017 ◽  
Vol 2 (1) ◽  
pp. 9
Author(s):  
Isman Mulyadi Triatmoko ◽  
Sutjipto Sutjipto
Keyword(s):  
Cytotoxic Activity ◽  
Neutron Irradiation ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Glioblastoma Cells ◽  
Morphological Alterations ◽  
Boron Neutron Capture ◽  
Icp Ms ◽  
Biological Effectiveness

A study of the assessment criteria covers the synthesis and characterization of agent and test their biological effectiveness as boron neutron capture therapy (BNCT) agents in cancer treatment. The cellular uptake of this agent into the glioblastoma cells was assessed by boron analysis (ICP-MS) and by fluorescence imaging (confocal microscopy). The agent enters the glioblastoma cells exhibiting a similar profile, i.e., preferential accumulation in the cytoskeleton and membranes and a low cytotoxic activity (IC<sub>50</sub> values higher than 200 μM). The cytotoxic activity and cellular morphological alterations after neutron irradiation in the Research Reactor (&gt;10<sup>7</sup> neutrons cm<sup>−2</sup> s<sup>−1</sup>) were assessed by the MTT assay and by electron microscopy (TEM). Post neutron irradiation revealed that BNCT has a higher cytotoxic effect on the glioblastoma cells. Results provide a strong rationale for considering one of these compounds as a lead candidate for a new BNCT agent.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Sign in / Sign up

Export Citation Format

Share Document